A5027337911- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- T-cell and B-cell Immunology
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Cutaneous lymphoproliferative disorders research
- Monoclonal and Polyclonal Antibodies Research
- Multiple Myeloma Research and Treatments
- Radiopharmaceutical Chemistry and Applications
- Antifungal resistance and susceptibility
- Virus-based gene therapy research
- Head and Neck Cancer Studies
- Oral health in cancer treatment
- Reproductive System and Pregnancy
- Immunodeficiency and Autoimmune Disorders
- CNS Lymphoma Diagnosis and Treatment
- Cancer Risks and Factors
- Viral Infectious Diseases and Gene Expression in Insects
- HIV/AIDS oral health manifestations
- Neutropenia and Cancer Infections
Universitätsmedizin Göttingen
2007-2024
University of Göttingen
2009-2024
University Medical Center
2021
Nephrologisches Zentrum Goettingen
2009-2014
Lutheran Hospital
2011
Froedtert Hospital
2011
Addenbrooke's Hospital
2011
University of Washington Medical Center
2004
Summary Background Invasive fungal diseases remain a major cause of morbidity and mortality in cancer patients undergoing intensive cytotoxic therapy. The choice the most appropriate antifungal treatment (AFT) depends on species suspected or identified, patient's risk factors (eg length depth granulocytopenia) expected side effects. Objectives Since last edition recommendations for ‘Treatment invasive infections patients’ Infectious Diseases Working Party (AGIHO) German Society Hematology...
Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact CH on safety, efficacy, outcome chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) 5), treated Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%), Brexucabtagene...
BACKGROUNDAdoptive transfer of EBV-specific T cells can restore specific immunity in immunocompromised patients with EBV-associated complications.METHODSWe provide results a personalized cell manufacturing program evaluating donor, patient, product, and outcome data. Patient-tailored clinical-grade cytotoxic lymphocyte (EBV-CTL) products from stem donors (SCDs), related third-party (TPDs), or unrelated TPDs the allogeneic donor registry (alloCELL) at Hannover Medical School were manufactured...
CD19-directed CAR-T-cells (CD19-CAR) have demonstrated remarkable clinical results in patients suffering from refractory or relapsed lymphoma and acute lymphoblastic leukemia. In order to further optimize follow-up, explain treatment failure, control adverse events biomarkers for monitoring of response are urgently needed. Peak expansion persistence correlated with rates severity side effects. However, no standardized method commercially assay CD19-CAR measurement is established yet. this...
Abstract Background Immunocompromised people (ICP) and elderly individuals (older than 80 years) are at increased risk for severe coronavirus infections. To protect against serious infection with SARS-CoV-2, ICP taking precautions that may include a reduction of social contacts participation in activities which they normally enjoy. Furthermore, these people, there is an uncertainty regarding the effectiveness vaccination. The COVID-19 Contact (CoCo) Immune study strives to characterize...
We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing small TP53-mutated clone. As third-line therapy, patient treated CAR-T cells, which resulted in complete remission. However, this treatment also led expansion clone and therapy-related myelodysplasia complex aberrant karyotype. This may serve as paradigmatic example clonal...
Target cell resistance against natural killer (NK) cell-mediated cytotoxicity obstructs NK cell-based immunotherapy of leukaemia. Several mechanisms have been described. Because lack simple assays for analysing these mechanisms, their relative impact on a given effector-target pair is mostly unknown. We here analysed the combination Granzyme B (GrB) enzyme-linked immunospot assay (ELISPOT) assessment reactivity and to estimate target escape mechanisms. recognition failure leads negative GrB...
Transformation from indolent non-Hodgkin lymphoma (NHL) to diffuse large B cell (DLBCL) has historically been associated with a poor prognosis. A small series of autologous stem transplantation (ASCT) studies using conventional conditioning regimens demonstrated durable progression-free survival (PFS) rates ranging 25% 47%, but data in the rituximab era are lacking. Here we report results multicenter retrospective trial evaluating ASCT patients transformed Z-BEAM regimen, which combines...
Initial treatment with the monoclonal anti-CD52 antibody alemtuzumab induces responses in majority of patients T-cell prolymphocytic leukemia (T-PLL). In eligible patients, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an option to consolidate hematological remissions. Here, we report our experience 10 who received allo-HSCT against T-PLL. Notably, 3 complete remission at and durable full-donor chimerism relapsed months 12, 59, 84 after transplantation, respectively. This...